ClinicalTrials.gg

Program

hemopexin (human)

Its studies are mostly in Vaso-Occlusive Crises · Anemia, Sickle Cell, led by CSL.

Furthest: phase 2, since Nov 19, 20242 company-led studies, 1 open or runningNext primary completion: Oct 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL21 open or runningphase 2since Nov 19, 2024Feb 24, 2020Oct 22, 2027phase 2 · NCT06699849

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2020First study: phase 1 study in Anemia, Sickle CellFirst studyNCT04285827 · 28 enrolled · United States, Netherlands, United Kingdom
  2. Nov 19, 2024Phase 2 study in Anemia, Sickle CellNCT06699849 · 70 planned · United States, Turkey (Türkiye), United Kingdom

Ahead

  1. Oct 22, 2027Primary completion: phase 2 study in Anemia, Sickle CellNCT06699849

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06699849Anemia, Sickle Cell · United States, Turkey (Türkiye), United Kingdom2RecruitingOct 22, 202770
NCT04285827Anemia, Sickle Cell · United States, Netherlands, United Kingdom1CompletedJul 24, 202328

How it is read

Names in the registry

  • “CSL889”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
hemopexin (human) (CSL): development program | ClinicalTrials.gg